Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Endometrial Neoplasms 1

Interventions

antineoplaston AS 2-1 3antineoplaston A10 3dactolisib 2Temozolomide 2Irinotecan 2Everolimus 2Bevacizumab 2surufatinib 1spartalizumab 1poly ICLC 1plerixafor 1pasireotide 1fosbretabulin 1cixutumumab 1adavosertib 1Vaccines 1TH 302 1Sunitinib 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1PM 00104 1Lapatinib 1Immunologic Techniques 1Immunoglobulin G 1Genistein 1Fentanyl 1Donepezil 1Disulfides 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡